Identifying Cognitive Impairment in the Acute Care Hospital Setting: Finding an Appropriate Screening Tool.

IMPORTANCE: Identifying cognitive impairment in adults in acute care is essential so that providers can address functional deficits and plan for safe discharge. Occupational therapy practitioners play an essential role in screening for, evaluating, and treating cognitive impairment. OBJECTIVE: To test and compare the psychometrics and feasibility of three cognitive screens and select the ideal screen for use in acute care. DESIGN: Prospective mixed methods. SETTING: Acute care hospital. PARTICIPANTS: Fifty adults. OUTCOMES AND MEASURES: We examined the interrater reliability, administration time, and usability of the Brief Cognitive Assessment Tool Short Form (BCAT-SF), the Activity Measure for Post-Acute Care "6-Clicks" Applied Cognitive Inpatient Short Form (AM-PAC ACISF), and the Montreal Cognitive Assessment (MoCA). We compared the construct validity, sensitivity, and specificity of the BCAT-SF and AM-PAC ACISF with those of the MoCA. RESULTS: Interrater reliability was good to excellent; ICCs were .98 for the MoCA, .97 for the BCAT-SF, and .86 for the AM-PAC ACISF. The BCAT-SF and the AM-PAC ACISF both had 100% sensitivity, and specificity was 74% for the BCAT-SF and 98% for the AM-PAC ACISF. The optimal cutoff score for cognitive impairment on the AM-PAC ACISF was <22. Administration time of the AM-PAC ACISF (1.0 min) was significantly less than that of the BCAT-SF (5.0 min) and the MoCA (13.3 min; p < .001). CONCLUSIONS AND RELEVANCE: Each screen demonstrated acceptable reliability and construct validity. The AM-PAC ACISF had the optimum mix of performance and feasibility for the fast-paced acute care setting. What This Article Adds: Early identification of cognitive impairment using the AM-PAC ACISF can allow for timely occupational therapy intervention in acute care settings.

Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care.

As of July 31, 2021, SARS-CoV-2 had infected almost 200 million people worldwide. The growing burden of survivorship is substantial in terms of the complexity of long-term health effects and the number of people affected. Persistent symptoms have been reported in patients with both mild and severe acute COVID-19, including those admitted to the intensive care unit (ICU). Early reports on the post-acute sequelae of SARS-CoV-2 infection (PASC) indicate that fatigue, dyspnoea, cough, headache, loss of taste or smell, and cognitive or mental health impairments are among the most common symptoms. These complex, multifactorial impairments across the domains of physical, cognitive, and mental health require a coordinated, multidisciplinary approach to management. Decades of research on the multifaceted needs of and models of care for patients with post-intensive care syndrome provide a framework for the development of PASC clinics to address the immediate needs of both hospitalised and non-hospitalised survivors of COVID-19. Such clinics could also provide a platform for rigorous research into the natural history of PASC and the potential benefits of therapeutic interventions.

Comparing a Novel Neuroanimation Experience to Conventional Therapy for High-Dose Intensive Upper-Limb Training in Subacute Stroke: The SMARTS2 Randomized Trial.

BACKGROUND: Evidence from animal studies suggests that greater reductions in poststroke motor impairment can be attained with significantly higher doses and intensities of therapy focused on movement quality. These studies also indicate a dose-timing interaction, with more pronounced effects if high-intensity therapy is delivered in the acute/subacute, rather than chronic, poststroke period. OBJECTIVE: To compare 2 approaches of delivering high-intensity, high-dose upper-limb therapy in patients with subacute stroke: a novel exploratory neuroanimation therapy (NAT) and modified conventional occupational therapy (COT). METHODS: A total of 24 patients were randomized to NAT or COT and underwent 30 sessions of 60 minutes time-on-task in addition to standard care. The primary outcome was the Fugl-Meyer Upper Extremity motor score (FM-UE). Secondary outcomes included Action Research Arm Test (ARAT), grip strength, Stroke Impact Scale hand domain, and upper-limb kinematics. Outcomes were assessed at baseline, and days 3, 90, and 180 posttraining. Both groups were compared to a matched historical cohort (HC), which received only 30 minutes of upper-limb therapy per day. RESULTS: There were no significant between-group differences in FM-UE change or any of the secondary outcomes at any timepoint. Both high-dose groups showed greater recovery on the ARAT (7.3 ± 2.9 points; P = .011) but not the FM-UE (1.4 ± 2.6 points; P = .564) when compared with the HC. CONCLUSIONS: Neuroanimation may offer a new, enjoyable, efficient, and scalable way to deliver high-dose and intensive upper-limb therapy.

A pilot study of eye-tracking devices in intensive care.

BACKGROUND: Eye-tracking devices have been suggested as a means of improving communication and psychosocial status among patients in the intensive care unit (ICU). This study was undertaken to explore the psychosocial impact and communication effects of eye-tracking devices in the ICU. METHODS: A convenience sample of patients in the medical ICU, surgical ICU, and neurosciences critical care unit were enrolled prospectively. Patients participated in 5 guided sessions of 45 minutes each with the eye-tracking computer. After completion of the sessions, the Psychosocial Impact of Assistive Devices Scale (PIADS) was used to evaluate the device from the patient's perspective. RESULTS: All patients who participated in the study were able to communicate basic needs to nursing staff and family. Delirium as assessed by the Confusion Assessment Method for the Intensive Care Unit was present in 4 patients at recruitment and none after training. The device's overall psychosocial impact ranged from neutral (-0.29) to strongly positive (2.76). Compared with the absence of intervention (0 = no change), patients exposed to eye-tracking computers demonstrated a positive mean overall impact score (PIADS = 1.30; P = .004). This finding was present in mean scores for each PIADS domain: competence = 1.26, adaptability = 1.60, and self-esteem = 1.02 (all P < .01). CONCLUSION: There is a population of patients in the ICU whose psychosocial status, delirium, and communication ability may be enhanced by eye-tracking devices. These 3 outcomes are intertwined with ICU patient outcomes and indirectly suggest that eye-tracking devices might improve outcomes. A more in-depth exploration of the population to be targeted, the device's limitations, and the benefits of eye-tracking devices in the ICU is warranted.

Comparisons of auditory steady state response and behavioral air conduction and bone conduction thresholds for infants and adults with normal hearing.

OBJECTIVE: To improve understanding of normal responses in infants by comparing air conduction (AC) and bone conduction (BC) auditory thresholds using both the auditory steady state response (ASSR) and behavioral testing methods in normal-hearing infants (6 to 18 months of age) and adults. At present, there are no correction factors available for estimating BC behavioral thresholds from BC ASSR thresholds, which is a barrier to clinical implementation of the ASSR. In addition, previous studies have reported infant-adult differences in AC and BC sensitivity, which suggest a "maturational" air-bone gap (ABG) that is not attributable to a conductive pathology; no study has yet compared AC and BC thresholds for either ASSR or behavioral methods in the same individuals. The objectives of the present study are: (1) to compare BC thresholds between methods and provide the initial step toward positing correction factors to predict BC behavioral thresholds, (2) to directly compare AC and BC thresholds to provide an accurate estimate of the maturational ABG, (3) to determine preliminary normal levels for BC and AC ASSRs to exponentially amplitude modulated stimuli, and (4) to investigate infant-adult differences in AC and BC thresholds using ASSRs and behavioral assessment tools. DESIGN: Participants were 23 infants (6.5 to 19.0 months of age) and 12 adults (17 to 50 years of age) with normal hearing. Thresholds were estimated at 500, 1000, 2000, and 4000 Hz using air- and bone-conducted stimuli for ASSRs and behavioral testing. The ASSR stimuli were exponential envelope modulated (amplitude modulation [AM]) at modulation frequencies of 78, 85, 93, and 101 Hz for 500, 1000, 2000, and 4000 Hz, respectively, presented simultaneously. Frequency-modulated (warble tone) stimuli were used for behavioral testing for both infants and adults, respectively. All stimuli were calibrated in dB HL. Thresholds were compared across frequency and between stimulus presentation modes, between age groups and assessment method. Normal levels for AC and BC ASSRs to AM stimuli were also calculated. RESULTS: The findings indicated that BC thresholds were, on average, 7 to 16 dB poorer for ASSR compared with visual reinforcement audiometry (VRA), but varied widely across infants. For infants, mean ABGs of 14 to 17 dB were found for low-frequency ASSR thresholds but mean ABGs for VRA thresholds were less than 10 dB. The preliminary normal levels for ASSR AM stimuli at 500, 1000, 2000, and 4000 Hz, respectively, were: (i) AC: 30, 30, 20, and 20 dB HL, and (ii) BC: 20, 20, 30, and 30 dB HL. There was a tendency for infant and adult ASSR thresholds to differ for BC, but not for AC. Behavioral thresholds for AC and BC were similar between infants and adults and across frequency. CONCLUSIONS: Infant-adult and AC-BC threshold differences are greater for ASSRs compared with behavioral measures. The results support the presence of a clinically significant maturational ABG in the low frequencies for infant ASSRs but not for VRA. The findings also show a significant offset between BC ASSR and BC VRA thresholds and large intersubject variability.

Creating an assistive technology clinic: the experience of the Johns Hopkins AT clinic for patients with ALS.

For persons with Amyotrophic Lateral Sclerosis (ALS), comprehensive multidisciplinary care can effectively improve overall quality of life from diagnosis to end of life [16]. Considering the rapidly progressive loss in overall function experienced by persons with ALS, it is essential to provide comprehensive multidisciplinary care, including Assistive Technology (AT) services, in an effective and efficient manner. AT is an important adjunctive therapy for people with neurological disability. For people with complex conditions, access to a comprehensive AT clinic can be the best way to access these tools. Unfortunately, few medical centers have invested in AT clinics, and managers may not understand how to go about developing AT resources at their facility. This article chronicles the step-by-step development of The Johns Hopkins Assistive Technology Clinic for persons with ALS. It offers background evidence, the process of program development, and insight into the experience of professional accountability of one occupational therapist turned AT Director. It also details descriptions of the stakeholders and their roles in the development process, funding and ethical considerations, and barriers to implementation. It is hoped that this may provide guidance for teams who may wish to build AT facilities in their own practice settings.